Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

NCT03801902 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03801902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03801902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
October 28, 2019
Completion date
September 4, 2025
Enrollment
26 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced lung non-small cell carcinoma, locally recurrent lung non-small cell carcinoma, stage ii lung cancer ajcc v8, stage iii lung cancer ajcc v8, unresectable lung non-small cell carcinoma